Welcome to our dedicated page for Rcm Tech SEC filings (Ticker: RCMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RCM Technologies, Inc. filings document the reporting obligations of a Nevada-incorporated operating company with common stock registered on Nasdaq under the symbol RCMT. Its Form 8-K reports cover financial results, material agreements, revolving credit and loan amendments, direct financial obligations, changes in certifying accountants, and related internal control disclosures.
The company’s proxy materials address board matters, executive compensation, equity award information, and pay-versus-performance disclosure. Periodic and notice filings provide formal records around annual reporting, late-filing notifications, consolidated financial statements, risk and control matters, and the governance framework supporting RCM Technologies’ health care, engineering, information technology, life sciences, data, and solutions services.
RCM Technologies, Inc. Division President, HC Srvs., Michael Saks reported open-market sales of company common stock. He sold a total of 5,000 shares at $30.00 per share in transactions on April 15–16, 2026. Following these sales, he directly owns 104,814 shares of common stock, which include 267 shares purchased through the company’s Employee Stock Purchase Plan. The filing notes that the sales were made under a nondiscretionary Rule 10b5-1 trading plan established on December 6, 2024.
RCM Technologies Executive Chairman & President Bradley Vizi sold 50,000 shares of common stock in open-market transactions at about $30.00 per share. The sales occurred on two dates and were executed under a nondiscretionary plan intended to satisfy Rule 10b5-1.
After these transactions, Vizi directly holds 1,502,477 shares of RCM Technologies common stock, indicating he retains a substantial ownership stake while realizing some liquidity through a pre-established trading plan.
RCMT filing reports an offering and recent Section 144 sale by an employee. The filing lists 4,864 common shares associated with an Employee Stock Purchase Plan and shows 136 shares sold on 04/15/2026 for $4,080.00. The filing was recorded on 04/16/2026.
RCM Technologies Executive Chairman & President Bradley Vizi reported a mix of stock sales and awards in company shares. On April 7–8, he sold 13,666 and 8,237 shares of common stock in open‑market transactions at weighted average prices around $27.55 and $27.52, executed under a nondiscretionary Rule 10b5‑1 trading plan.
He also received 104,266 shares as employment compensation upon vesting of previously granted performance stock units, while 41,029 shares were surrendered to cover related tax obligations through a net share settlement. After these transactions, Vizi directly holds 1,552,477 shares of RCM Technologies common stock, indicating the sales represent a small portion of his overall stake.
RCM Technologies, Inc. submitted a Form 144 notifying proposed sale of Common Stock tied to restricted‑share vesting. The notice lists 96,933 shares dated 01/15/2021, 125,000 shares dated 01/03/2023, and 50,000 shares dated 01/16/2023.
The filing identifies the securities as Common Stock, par value $0.05 and references NASDAQ with a filing date line showing 04/07/2026.
RCM Technologies, Inc. files its annual report, reporting revenue of $319.4 million for the year ended January 3, 2026, up from $278.4 million a year earlier. Specialty Health Care generated 51.4% of revenue, Engineering 37.7%, and Life Sciences, Data and Solutions 10.9%.
The company highlights growing demand tied to telemedicine, behavioral health, cleaner energy infrastructure, and hybrid IT solutions. Two customers accounted for 20.8% and 13.6% of consolidated revenue, and about 9.1% of revenue came from outside the United States.
RCM remained in compliance with its revolving credit covenants, with $24.7 million borrowed and $27.1 million available, and continued a $50 million share repurchase program, buying 114,942 shares in late 2025 at an average price of $19.48.
RCM Technologies, Inc. reported strong growth for the fourteen weeks ended January 3, 2026, with revenue of $86.5 million, up 12.4% from $76.9 million in the prior-year quarter. Gross profit rose to $24.3 million, and GAAP net income more than doubled to $6.1 million, or $0.80 per diluted share.
For the fifty-three-week fiscal year, revenue increased 14.7% to $319.4 million, while gross profit reached $87.9 million. GAAP net income grew to $16.3 million, or $2.14 per diluted share. Adjusted EBITDA improved to $30.7 million, and adjusted diluted EPS climbed to $2.50, reflecting broad-based operational strength.
RCM Technologies, Inc. notifies the SEC that it will not timely file its Annual Report on Form 10-K for the fiscal year ended January 3, 2026 because additional time is needed to finalize consolidated financial statements. The company expects to file within the fifteen calendar day extension provided by Rule 12b-25.
RCM Technologies, Inc. amended its senior credit facility with Citizens Bank to temporarily expand borrowing capacity. Under Amendment No. 1, the total revolving commitment rises from $65,000,000 to $75,000,000 from February 20, 2026 through August 31, 2026, including availability for trade and standby letters of credit.
From September 1, 2026 through the loan’s maturity, the commitment reverts to $65,000,000, and any outstanding revolving loans above that level become immediately due and payable in full on that date. The amendment otherwise leaves the existing loan terms in place and reaffirms the lender’s first-priority security interest in the borrowers’ collateral.
Conditions to effectiveness include execution of the amendment, delivery of a Thirteenth Amended and Restated Revolving Credit Note reflecting the new commitment, updated corporate certificates and schedules, and payment of a $15,000 amendment fee. The borrowers also grant a broad release of claims in favor of Citizens Bank and agree to reimburse costs and expenses related to the amendment.